Compare DSX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | CRDL |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Greece | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 226.6M |
| IPO Year | 2005 | 2017 |
| Metric | DSX | CRDL |
|---|---|---|
| Price | $2.73 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 911.8K | ★ 1.4M |
| Earning Date | 05-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.28 | N/A |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.88 |
| 52 Week High | $2.92 | $2.28 |
| Indicator | DSX | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 64.34 | 65.19 |
| Support Level | $2.27 | $0.95 |
| Resistance Level | $2.90 | N/A |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 86.73 | 59.76 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize, and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods, including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers, through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation; the services provided by the vessels are similar, and all operate under the same economic environment.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.